Endocannabinoids and traumatic brain injury

British Journal of Pharmacology

Volumn 163, Issue 7, 2011, Pages 1402-1410

  Shohami, Esther ^a   Cohen Yeshurun, Ayelet ^a   Magid, Lital ^a   Algali, Merav ^a   Mechoulam, Raphael ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

2 arachidonoyl glycerol; brain injury; N arachidonoyl L serine; neuroprotection

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ALPHA DIACYLGLYCEROL LIPASE; BETA DIACYLGLYCEROL LIPASE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; HU 910; LIPOPROTEIN LIPASE; N ARACHIDONOYL L SERINE; SERINE; UNCLASSIFIED DRUG; ANANDAMIDE; CANNABINOID RECEPTOR; CENTRAL NERVOUS SYSTEM AGENTS; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPROTEIN LIPASE ALPHA; LIPOPROTEIN LIPASE BETA; N ARACHIDONOYL LEVO SERINE; NEUROPROTECTIVE AGENT; TUMOR NECROSIS FACTOR ALPHA; VANILLOID RECEPTOR 1;

ANTIINFLAMMATORY ACTIVITY; DRUG INHIBITION; EXCITOTOXICITY; HUMAN; INFLAMMATION; MICROVASCULATURE; NERVOUS SYSTEM DEVELOPMENT; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRAUMATIC BRAIN INJURY; BRAIN BLOOD VESSEL; BRAIN EDEMA; CALCIUM TRANSPORT; CELL PROTECTION; CELL SURVIVAL; DRUG EFFECT; DRUG RESEARCH; EXPERIMENTAL MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; PROTEIN EXPRESSION; VASODILATATION;

ANIMALS; BRAIN; BRAIN INJURIES; ENDOCANNABINOIDS; HUMANS; RECEPTORS, CANNABINOID;

EID: 79960333360     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01343.x     Document Type: Review

References (93)

1. Aguado T, Monory K, Palazuelos J, Stella N, Cravatt B, Lutz B, (2005). The endocannabinoid system drives neural progenitor proliferation. FASEB J 19: 1704-1706. (Pubitemid 41429536)
2. Aguado T, Palazuelos J, Monory K, Stella N, Cravatt B, Lutz B, et al,. (2006). The endocannabinoid system promotes gliogenesis by acting on neural progenitor cells. J Neurosci 26: 1551-1561. (Pubitemid 43237025)
3. Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I, (2000). Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neurosci 100: 685-688.
4. Alessandri B, Landolt H, Langemann H, Gregorin J, Hall J, Gratzl O, (1996). Application of glutamate in the cortex of rats: a microdialysis study. Acta Neurochir Suppl 67: 6-12. (Pubitemid 126446193)
5. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 158 (Suppl. 1): S1-S254.
6. Ashton JC, Glass M, (2007). The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol 5: 73-80. (Pubitemid 47019422)
7. Assaf Y, Holokovsky A, Berman E, Shapira Y, Shohami E, Cohen Y, (1999). Diffusion and perfusion MRI following closed head injury in rats. J Neurotrauma 16: 1165-1176. (Pubitemid 30013317)
8. Bahr BA, Karanian DA, Makanji SS, Makriyannis A, (2006). Targeting the endocannabinoid system in treating brain disorders. Expert Opin Investig Drugs 15: 351-365.
9. Barone FC, Ohlstein EH, Hunter AJ, Campbell CA, Hadingham SH, Parsons A, et al,. (2000). Selective antagonism of ETA receptors improves outcome in both head trauma and focal stroke. J Cardiovasc Pharmacol 36 (Suppl. 1): S357-S361.
10. Basavarajappa BS, (2007). Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Curr Neuropharmacol 5: 81-97. (Pubitemid 47019423)
11. Beauchamp K, Mutlak H, Smith WR, Shohami E, Stahel PF, (2008). Pharmacology of traumatic brain injury-where is the 'golden bullet'? Mol Med 14: 731-740.
12. Beit-Yannai E, Kohen R, Horowitz M, Trembovler V, Shohami E, (1997). Changes in biological reducing activity in rat brain following closed head injury: a cyclic voltammetry study in normal and acclimated rats. J Cereb Blood Flow & Metabol 17: 273-279. (Pubitemid 27161370)
13. Beni SM, Kohen R, Reiter RJ, Tan D-X, Shohami E, (2004). Melatonin-induced neuroprotection after closed head injury is associated with increased brain antioxidants and attenuated late-phase activation of NF-κB and AP-1. FASEB J 18: 149-151.
14. Benito C, Kim WK, Chavarria I, Hillard CJ, Mackie K, Tolon RM, et al,. (2005). A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J Neurosci 25: 2530-2536. (Pubitemid 40365164)
15. Benito C, Tolõn RM, Pazos MR, Núñez E, Castillo AI, Romero J, (2008). Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol 153: 277-285.
16. Berrendero F, Sepe N, Ramos JA, Di Marzo V, Fernández-Ruiz JJ, (1999). Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse 33: 181-191. (Pubitemid 29372845)
17. Bisogno T, Berrendero F, Ambrosino G, Cebeira M, Ramos JA, Fernandez-Ruiz JJ, et al,. (1999). Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun 256: 377-380. (Pubitemid 29298893)
18. Brown JI, Baker AJ, Konasiewicz SJ, Moulton RJ, (1998). Clinical significance of CSF glutamate concentrations following severe traumatic brain injury in humans. J Neurotrauma 15: 253-263. (Pubitemid 28166577)
19. Cabral GA, Marciano-Cabral F, (2005). Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J Leukoc Biol 78: 1192-1197. (Pubitemid 41779223)
20. Carrier EJ, Kearn CS, Barkmeier AJ, Breese NM, Yang W, Nithipatikom K, et al,. (2004). Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol 65: 999-1007. (Pubitemid 38420506)
21. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D, (1997). The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389: 816-824. (Pubitemid 27462969)
22. Centonze D, Bari M, Rossi S, Prosperetti C, Furlan R, Fezza F, et al,. (2007). The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 130: 2543-2553. (Pubitemid 47511703)
23. Chan PH, (2001). Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 21: 2-14. (Pubitemid 32036708)
24. Chen Y, McCarron RM, Bembry J, Ruetzler C, Azzam N, Lenz FA, et al,. (1999). Nitric oxide modulates endothelin 1-induced Ca2+ mobilization and cytoskeletal F-actin filaments in human cerebromicrovascular endothelial cells. J Cereb Blood Flow Metabol 19: 133-138. (Pubitemid 29284260)
25. Chen Y, McCarron RM, Ohara Y, Bembry J, Azzam N, Lenz FA, et al,. (2000). A novel functional interaction between 2-arachidonoglycerol, an endocannabinoid, and endothelin-1 in human brain capillary endothelium. Circ Res 87: 323-327. (Pubitemid 30655974)
26. Cohen RA, Vanhoutte PM, (1995). Endothelium-dependent hyperpolarization beyond nitric oxide and cyclic GMP. Circulation 92: 3337-3349.
27. Cohen-Yeshurun A, Leker R, Mechoulam R, Shohami E, (2007). The endocannabinoid-like N-arachidonoyl-L-serine improves outcome after traumatic brain injury. (abs) Israel Society for Neuroscience meeting, Eilat, Israel.
28. Cohen-Yeshurun A, Trembovler V, Alexandrovich AG, Ryberg E, Greasley PJ, Mechoulam R, et al,. (2009). Neuroprotection and induction of stem cells proliferation and migration by N-arachidonoyl-L-serine: an endocannabinoid-like brain constituent. (abs) Israel Society for Neuroscience meeting, Eilat, Israel.
29. Coomber B, O'Donoghue MF, Mason R, (2008). Inhibition of endocannabinoid metabolism attenuates enhanced hippocampal neuronal activity induced by kainic acid. Synapse 62: 746-755.
30. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al,. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98: 9371-9376. (Pubitemid 32743923)
31. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al,. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949. (Pubitemid 23026736)
32. Di Marzo V, Bisogno T, De Petrocellis L, (2001). Anandamide: some like it hot. Trends Pharmacol Sci 22: 346-349. (Pubitemid 32592472)
33. Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, et al,. (2005). Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 12: 2-29.
34. Elgali M, Alexandrovich AG, Trembovler V, Magid L, Mechoulam R, Shohami E, (2009). Dynamic Changes of the endocannabinoid receptors and synthesizing enzymes after traumatic brain injury: effect of a CB2 receptor agonist. (abs) Israel Society for Neuroscience meeting, Eilat, Israel.
35. Faden AI, Demediuk P, Panter SS, Vink R, (1989). The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 244: 798-800. (Pubitemid 19163864)
36. Finfer SR, Cohen J, (2001). Severe traumatic brain injury. Resuscitation 48: 77-90. (Pubitemid 32121667)
37. Franklin A, Stella N, (2003). Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol- sensitive receptors. Eur J Pharmacol 474: 195-198. (Pubitemid 37281448)
38. Gallily R, Breuer A, Mechoulam R, (2000). 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur J Pharmacol 406: R5-R7.
39. Galve-Roperh I, Rueda D, Gõmez Del Pulgar T, Velasco G, Guzman M, (2002). Mechanism of extracellular signal-regulated kinase activation by the CB1 cannabinoid receptor. Mol Pharmacology 62: 1385-1392. (Pubitemid 35403833)
40. Galve-Roperh I, Aguado T, Palazuelos J, Guzmán M, (2007). The endocannabinoid system and neurogenesis in health and disease. Neuroscientist 13: 109-114. (Pubitemid 46524315)
41. Gao Y, Vasilyev DV, Goncalves MB, Howell FV, Hobbs C, Reisenberg M, et al,. (2010). Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci 30: 2017-2024.
42. Gilbert GL, Kim HJ, Waataja JJ, Thayer SA, (2007). Delta9- tetrahydrocannabinol protects hippocampal neurons from excitotoxicity. Brain Res 1128: 61-69. (Pubitemid 46055239)
43. Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R, et al,. (2004). Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 132: 87-92. (Pubitemid 39531355)
44. Hajos N, Katona I, Naiem SS, MacKie K, Ledent C, Mody I, et al,. (2000). Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 12: 3239-3249.
45. Hajos N, Ledent C, Freund TF, (2001). Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neurosci 106: 1-4. (Pubitemid 32831068)
46. Hayes RL, Jenkins LW, Lyeth BG, Balster RL, Robinson SE, Clifton GL, et al,. (1988). Pretreatment with phencyclidine, an N-methyl-D-aspartate antagonist, attenuates long-term behavioral deficits in the rat produced by traumatic brain injury. J Neurotrauma 5: 259-274. (Pubitemid 19137963)
47. Hwang J, Adamson C, Butler D, Janero DR, Makriyannis A, Bahr BA, (2010). Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Life Sciences 86: 615-623.
48. Kalia LV, Kalia SK, Salter MW, (2008). NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 7: 742-755. (Pubitemid 351957932)
49. Karanian DA, Brown QB, Makriyannis A, Kosten TA, Bahr BA, (2005). Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J Neurosci 25: 7813-7820. (Pubitemid 41208653)
50. Karin M, Ben-Neriah Y, (2000). Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-663. (Pubitemid 30365393)
51. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, et al,. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81. (Pubitemid 36098263)
52. Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N, et al,. (2001). Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 21: 9506-9518. (Pubitemid 33096895)
53. Koch M, Kreutz S, Böttger C, Grabiec U, Ghadban C, Korf HW, et al,. (2010). The cannabinoid WIN 55,212-2-mediated protection of dentate gyrus granule cells is driven by CB1 receptors and modulated by TRPA1 and Cav2.2 channels. Hippocampus [Epub ahead of print].
54. Leker RR, Shohami E, (2002). Cerebral ischemia and trauma-different etiologies yet similar mechanisms: neuroprotective opportunities. Brain Res Rev 39: 55-73. (Pubitemid 34666986)
55. Lynch DR, Dawson TM, (1994). Secondary mechanisms in neuronal trauma. Curr Opin Neurol 7: 510-516. (Pubitemid 24365662)
56. Mackie K, (2006). Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46: 101-122.
57. McHugh D, Hu SS, Rimmerman N, Juknat A, Vogel Z, Walker JM, et al,. (2010). N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 11: 44-58.
58. 2 receptor agonists as potential neuroprotective agents in traumatic brain injury. (abs) Israel Society for Neuroscience meeting, Eilat, Israel.
59. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN, (2005). Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95: 437-445. (Pubitemid 41457512)
60. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, et al,. (2003). CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302: 84-88. (Pubitemid 37210691)
61. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al,. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
62. Mechoulam R, Fride E, Ben-Shabat S, Meiri U, Horowitz M, (1998). Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur J Pharmacol 362: R1-R3. (Pubitemid 29001003)
63. Mezey E, Tõth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R, et al,. (2000). Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A 97: 3655-3660. (Pubitemid 30183358)
64. Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Batkai S, et al,. (2006). N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A 103: 2428-2433. (Pubitemid 43271686)
65. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, et al,. (1999). Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19: 2987-2995. (Pubitemid 29173995)
66. Onaivi ES, (2009). Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. Int Rev Neurobiol 88: 335-369. Review.
67. Ozaita A, Puighermanal E, Maldonado R, (2007). Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J Neurochem 102: 1105-1114. (Pubitemid 47174245)
68. Pacher P, Hasko G, (2008). Endocannabinoids and cannabinoid receptors in ischaemia reperfusion injury and preconditioning. Br J Pharmacol 153: 252-262.
69. Palazuelos J, Aguado T, Egia A, Mechoulam R, Guzmán M, Galve-Roperh I, (2006). Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J 20: 2405-2407.
70. Palazuelos J, Davoust N, Julien B, Hatterer E, Aguado T, Mechoulam R, et al,. (2008). The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem 283: 13320-13329.
71. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, et al,. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413: 527-531. (Pubitemid 32938751)
72. Panikashvili D, Mechoulam R, Beni SM, Alexandrovich A, Shohami E, (2005). CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J Cereb Blood Flow Metab 25: 477-484.
73. Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, et al,. (2006). The endocannabinoid 2-AG protects the blood brain barrier after closed head injury and inhibits expression of proinflammatory cytokines. Neurobiol Dis 22: 257-264.
74. Pertwee RG, (2008). Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 13: 147-159. (Pubitemid 351698890)
75. Piomelli D, (2003). The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873-884. (Pubitemid 37351427)
76. Piomelli D, Beltramo M, Giuffrida A, Stella N, (1998). Endogenous cannabinoid signaling. Neurobiol Dis 5: 462-573.
77. Randall MD, Kendall DA, (1998). Endocannabinoids: a new class of vasoactive substances. J Trends Pharmacol Sci 19: 55-58. (Pubitemid 28137714)
78. Schlicker E, Kathmann M, (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22: 565-572. (Pubitemid 33042646)
79. Schweitzer P, (2000). Cannabinoids decrease the K(+) M-current in hippocampal CA1 neurons. J Neurosci 20: 51-58. (Pubitemid 30220490)
80. Shen M, Thayer SA, (1998). Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 54: 459-462. (Pubitemid 28442938)
81. Shen M, Piser TM, Seybold VS, Thayer SA, (1996). Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 16: 4322-4334. (Pubitemid 26243028)
82. Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T, (1997). Cytokine productionin the brain following closed head injury: Dexanabinol (HU-211) is a novel TNFα inhibitor and an effective neuroprotectant. J Neuroimmunol 72: 169-177. (Pubitemid 27062773)
83. Shohami E, Ginis I, Hallenbeck JM, (1999). Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev 10: 119-130. (Pubitemid 29446376)
84. Sinor AD, Irvin SM, Greenberg DA, (2000). Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett 278: 157-160. (Pubitemid 30009481)
85. Stahel PF, Smith WR, Bruchis J, Rabb CH, (2008). Peroxisome proliferator-activated receptors: 'key' regulators of neuroinflammation after traumatic brain injury. PPAR Res 2008: 538141.
86. Stella N, (2010). Cannabinoid and cannabinoid-like receptors in microglia, astrocytes. and astrocytomas. Glia 58: 1017-1030.
87. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al,. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 89-97.
88. Tolias CM, Bullock MR, (2004). Critical appraisal of neuroprotection trials in head injury: what have we learned? NeuroRx 1: 71-79. (Pubitemid 46589341)
89. Varga K, Wagner JA, Bridgen DT, Kunos G, (1998). Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12: 1035-1044. (Pubitemid 28359585)
90. Vink R, Nimmo AJ, (2009). Multifunctional drugs for head injury. Neurotherapeutics 6: 28-42.
91. Zhang M, Martin BR, Adler MW, Razdan RK, Jallo JI, Tuma RF, (2007). Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab 27: 1387-1396. (Pubitemid 46985356)
92. Zhang M, Martin BR, Adler MW, Razdan RJ, Kong W, et al,. (2009). Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimmine Pharmacol 4: 249-259.
93. Ziebell JM, Morganti-Kossmann MC, (2010). Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherap 7: 22-30.